Metformin for Prevention and Treatment of Colon Cancer: A Reappraisal of Experimental and Clinical Data

Author(s): Vladimir N. Anisimov

Journal Name: Current Drug Targets

Volume 17 , Issue 4 , 2016

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


In the 70-80th of last century, it has been shown that the antidiabetic biguanide drugs phenformin (PF) and buformin (BF) can exert an inhibitory action on carcinogenesis in animal models and increase from 5 to 10-years survival of cancer patients. Since 2005, after first evidence publication of the capacity of metformin (MF), another biguanide, to prevent development of malignant tumors in individuals with type 2 diabetes (T2D) and suppress tumorigenesis in mice, the burst of studies started in this field focused on breast, pancreas, prostatic, endometrial and some other cancers. Colorectal cancer (CRC) is the most prevalent among digestive system cancers. In this mini-review are presented the available data on the capacity of antidiabetic biguanide drugs to prevent colorectal carcinogenesis and growth in vitro and in vivo in experimental models and clinical observations.

Keywords: Colorectal cancer, metformin, prevention, treatment.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2016
Published on: 12 February, 2016
Page: [439 - 446]
Pages: 8
DOI: 10.2174/1389450116666150309113305
Price: $65

Article Metrics

PDF: 39
PRC: 1